Delivery Order SPE2DB20D9331-SPE2DB25FL1K1

Award Date 6/9/25
Potential Completion Date 7/1/25
Potential Value $27K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $27,343.62 contract was awarded by the Defense Logistics Agency (DLA) for the supply of PERJETA 420 MG/14 ML VIAL 14ML, a specialty oncology medication. The award is not associated with a set-aside program. DMS Pharmaceutical Group holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $36,458.16, is for the delivery of 4566859449 - PERJETA 420 MG/14 ML VIAL 14ML, a specialized pharmaceutical product. The contract is not associated with any set-aside designation. DMS Pharmaceutical Group Inc. also holds a significant single-award Indefinite...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is valued at $34,039.68 and has an ultimate completion date of July 19, 2024. The contract is for the delivery of the pharmaceutical product PERJETA 420 MG/14 ML VIAL 14ML, with no set-aside designation. DMS Pharmaceutical Group Inc. holds a significant indefinite...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a for-profit, woman-owned small business located in Park Ridge, Illinois. The $25,529.76 contract is for the supply of 4564110226 PERJETA 420 MG/14 ML VIAL 14ML, with a performance period through April 16, 2024. DMS Pharmaceutical Group Inc. holds a larger indefinite delivery contract (IDV) with the DLA, valued up to $4,999,999 through 2025, which enables the agency to...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $25,529.76, is for the delivery of PERJETA (420 mg/14 ml) vials to support the recurring medical supply needs of Department of Defense (DoD) healthcare facilities. DMS Pharmaceutical Group holds a larger indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract has a ceiling value of $45,572.70 and an ultimate completion date of March 17, 2025. The award is for the delivery of 4567394636 - PERJETA 420 MG/14 ML VIAL 14ML, a specialized oncology medication. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $15,756.60 contract covers the delivery of 4556522685 - PERJETA 420 MG/14 ML VIAL 14ML, a specialized oncology medication, to support the medical supply needs of military healthcare facilities. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the...
The U.S. Department of Defense, through the Defense Logistics Agency (DLA), awarded a firm fixed-price delivery order contract valued at $8,509.92 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the delivery of 4566529142 - PERJETA 420 MG/14 ML VIAL 14ML, a specialized pharmaceutical product, with a performance period through December 12, 2024. This delivery order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC)...
The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract, valued at $25,529.76, is for the delivery of 4563651600 - PERJETA 420 MG/14 ML VIAL 14ML. This delivery order is issued under DMS Pharmaceutical Group's broader indefinite delivery contract (IDC) with the DLA, contract 4600082013 under the SPE2DB program, valued up to $4,999,999 through 2025. The IDC...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract has a ceiling value of $25,529.76 and is for the delivery of 4566802452, which is identified as PERJETA 420 MG/14 ML VIAL 14ML. This is a specialized oncology medication that will be provided to support the recurring medical supply needs of military healthcare facilities and...
  • SPE2DB20D9331
    Indefinite Delivery Contract
  • SPE2DB20D9331-SPE2DB25FL1K1
    Delivery Order

This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $27,343.62 contract is for the delivery of PERJETA 420 MG/14 ML VIAL 14ML and does not have a set-aside designation.

DMS Pharmaceutical Group holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026. This IDC enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items supporting medical supply needs of military health facilities worldwide. The contract covers an extensive portfolio of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables across various product categories.

Generated 9/14/25, 12:52 AM